BerGenBio ASA: BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

BERGEN, Norway, Sept. 27, 2022 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

Related Keywords

Oslo ,Norway ,United Kingdom ,France ,Norwegian ,Graham Morrell ,Martin Olin ,Prnewswire Bergenbio ,Linstitut National De La Sant ,Oslo University Hospital ,European Clinical Research Infrastructure Network ,Oslo Stock Exchange ,European Discovery ,Emerging Infection Platform Trial ,Chief Executive Officer ,Chief Investigator ,Senior Consultant ,Oslo University ,University Hospital ,Norwegian Securities Trading ,Bergenbio ,Annouces ,First ,Patient ,Randomized ,Emcentinib ,Trial ,Olidact ,Platform ,Hospitalized ,Covid ,Patients ,